AYJ Stock Chart & Stats
€2.78
-€0.06(-2.90%)
At close: 4:00 PM EDT
€2.78
-€0.06(-2.90%)
Day’s Range― - ―
52-Week Range€2.04 - €5.13
Previous CloseN/A
Volume52.05K
Average Volume (3M)11.50K
Market Cap
€477.72M
Enterprise Value€516.36M
Total Cash (Recent Filing)€121.53M
Total Debt (Recent Filing)€210.23M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Nov 12, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding189,771,240
10 Day Avg. Volume7,605
30 Day Avg. Volume11,499
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)5.89
Price to Sales (P/S)3.58
P/FCF Ratio-10.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.44
Revenue Forecast (FY)€151.44M
Bulls Say, Bears Say
Bulls Say
Lyme Vaccine Pipeline DifferentiationThe Lyme program offers meaningful strategic upside because clinical efficacy and safety data have advanced into regulatory review. As the only late-stage candidate noted, successful approval could create a differentiated product and materially broaden Valneva’s commercial platform over several years.
Restructuring And Cost DisciplineRestructuring and lower operating expenses can improve the company’s cost base beyond the current reporting period. If execution is effective, reduced spending and sharper project prioritization should support gross-margin recovery, limit cash burn, and improve operating leverage as products grow.
Established Commercial Vaccine BaseThe marketed portfolio already generates substantial product revenue across Japanese encephalitis, cholera, and chikungunya vaccines. This commercial foundation provides customer access, operating experience, and a potential source of recurring cash generation while the company develops newer pipeline opportunities.
Bears Say
Material Revenue ContractionA sharp year-over-year revenue decline weakens the scale needed to absorb fixed costs and fund research internally. Continued pressure across product sales, together with the loss of prior one-off revenue, could make the business more dependent on successful launches, partnerships, or external financing.
Severe Margin And Profitability DeteriorationThe widening operating and EBITDA losses show that current revenue is not covering the company’s cost structure. Persistent earnings weakness reduces internal investment capacity and makes future profitability dependent on restoring product margins, controlling expenses, and converting pipeline assets into revenue.
Ongoing Cash Burn And Weaker Balance-sheet CushionSustained negative cash generation means Valneva may need debt or equity funding to maintain operations and develop its pipeline. Combined with a shrinking equity base and higher leverage, ongoing losses reduce financial flexibility and increase the consequences of execution setbacks.
Valneva News
AYJ FAQ
What was Valneva SE’s price range in the past 12 months?
Valneva SE lowest stock price was €2.04 and its highest was €5.13 in the past 12 months.
What is Valneva SE’s market cap?
Valneva SE’s market cap is €477.72M.
When is Valneva SE’s upcoming earnings report date?
Valneva SE’s upcoming earnings report date is Nov 12, 2026 which is in 25 days.
How were Valneva SE’s earnings last quarter?
Valneva SE released its earnings results on Aug 13, 2026. The company reported -€0.17 earnings per share for the quarter, missing the consensus estimate of -€0.089 by -€0.081.
Is Valneva SE overvalued?
According to Wall Street analysts Valneva SE’s price is currently Overvalued.
Does Valneva SE pay dividends?
Valneva SE does not currently pay dividends.
What is Valneva SE’s EPS estimate?
Valneva SE’s EPS estimate is -0.09.
How many shares outstanding does Valneva SE have?
Valneva SE has 189,771,240 shares outstanding.
What happened to Valneva SE’s price movement after its last earnings report?
Valneva SE reported an EPS of -€0.17 in its last earnings report, missing expectations of -€0.089. Following the earnings report the stock price went down -3.175%.
Which hedge fund is a major shareholder of Valneva SE?
Currently, no hedge funds are holding shares in DE:AYJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valneva SE
Valneva SE is a specialized biotechnology company focused on developing and bringing to market preventative vaccines for infectious diseases with significant unmet medical needs. Their commercial offerings for travelers include IXIARO, a vaccine against Japanese encephalitis, and DUKORAL, an oral vaccine designed to protect against diarrhea caused by Vibrio cholera and specific heat-labile toxin-producing Enterotoxigenic Escherichia coli. The company also progressed VLA2001, a vaccine candidate targeting SARS-CoV-2. In its development pipeline, Valneva has VLA15, a Lyme disease vaccine candidate that has concluded Phase II clinical trials, and VLA1553, a chikungunya virus vaccine candidate currently undergoing Phase III evaluation. The company distributes its products across the United States, Canada, various European nations including Germany, Austria, the Nordics, and the United Kingdom, as well as other global markets. Valneva SE has established strategic partnerships, notably with Pfizer, Inc. for the joint development and commercialization of its Lyme disease vaccine, and with Instituto Butantan for the creation, manufacturing, and marketing of a single-shot chikungunya vaccine. The company was established in 1998 and operates from its headquarters in Saint-Herblain, France.